Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$3.14 - $3.9 $50,240 - $62,400
-16,000 Closed
0 $0
Q2 2021

Aug 12, 2021

SELL
$3.8 - $4.56 $1,900 - $2,280
-500 Reduced 3.03%
16,000 $62,000
Q1 2021

May 13, 2021

BUY
$4.33 - $6.63 $71,445 - $109,395
16,500 New
16,500 $76,000
Q4 2020

Feb 09, 2021

SELL
$4.87 - $17.29 $58,440 - $207,480
-12,000 Closed
0 $0
Q3 2020

Nov 06, 2020

SELL
$15.08 - $27.04 $12,802 - $22,956
-849 Reduced 6.61%
12,000 $197,000
Q1 2020

May 11, 2020

SELL
$10.27 - $21.23 $363,948 - $752,348
-35,438 Reduced 73.39%
12,849 $191,000
Q4 2019

Feb 13, 2020

BUY
$8.36 - $23.81 $320,079 - $911,613
38,287 Added 382.87%
48,287 $988,000
Q3 2019

Nov 12, 2019

SELL
$9.83 - $14.82 $17,939 - $27,046
-1,825 Reduced 15.43%
10,000 $98,000
Q2 2019

Aug 13, 2019

BUY
$12.9 - $20.8 $12,900 - $20,800
1,000 Added 9.24%
11,825 $160,000
Q1 2019

May 14, 2019

BUY
$17.7 - $24.93 $29,859 - $42,056
1,687 Added 18.46%
10,825 $213,000
Q4 2018

Feb 14, 2019

SELL
$19.05 - $36.45 $10,477 - $20,047
-550 Reduced 5.68%
9,138 $207,000
Q3 2018

Nov 13, 2018

SELL
$34.41 - $44.23 $103,229 - $132,690
-3,000 Reduced 23.64%
9,688 $360,000
Q2 2018

Aug 13, 2018

SELL
$39.21 - $50.29 $8,822 - $11,315
-225 Reduced 1.74%
12,688 $497,000
Q1 2018

May 15, 2018

BUY
$41.7 - $64.16 $250,742 - $385,794
6,013 Added 87.14%
12,913 $635,000
Q4 2017

Feb 14, 2018

BUY
$28.58 - $49.91 $197,202 - $344,379
6,900
6,900 $312,000

Others Institutions Holding ASMB

# of Institutions
1
Shares Held
16.3K
Call Options Held
0
Put Options Held
0

About ASSEMBLY BIOSCIENCES, INC.


  • Ticker ASMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,436,900
  • Market Cap $647M
  • Description
  • Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...
More about ASMB
Track This Portfolio

Track Blair William & CO Portfolio

Follow Blair William & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.